Company Overview
NeoGenomics, Inc. operates a specialized network of cancer-focused testing laboratories with a physical presence in both the United States and the United Kingdom, providing essential diagnostic services to a diverse clientele that includes hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. The company functions within the healthcare sector, specifically targeting the diagnostics and research industry, which positions it to capitalize on the increasing demand for genomic profiling and precision medicine solutions. Its current market capitalization stands at $1.02B, while the firm generated $727.33M in annual revenue (TTM) and employs a workforce of 2500 individuals. These valuation and revenue figures indicate that NeoGenomics has established a significant foothold in the specialized oncology diagnostics market, supporting a substantial operational infrastructure and serving a broad range of healthcare partners across two major geographic regions.
Financial Health
The company reported a revenue of $727.33M (TTM) alongside a net income of $-108,025,000 and an EBITDA of $-1,821,000, revealing a cost structure where operating expenses significantly outweigh gross profits, resulting in a net loss despite a robust top-line. NeoGenomics maintains a free cash flow of $17.20M, which suggests that the company retains sufficient liquidity to fund operations and potentially invest in laboratory expansion or technology upgrades without relying solely on external financing. The firm's margin profile shows a gross margin of 43.2%, indicating that the company retains a healthy portion of revenue after direct costs, though an operating margin of -6.6% and a profit margin of -14.9% demonstrate that high overhead costs or research expenditures are suppressing overall profitability. On the balance sheet, the company holds $159.62M in cash against $409.46M in debt, resulting in a debt-to-equity ratio of 48.95, which characterizes the financial position as highly leveraged given the current lack of net income to service obligations. However, the current ratio stands at 4.26, indicating that the company possesses strong short-term liquidity and holds significantly more current assets than current liabilities. Return on Equity is reported at -12.4% and return on assets at -2.9%, metrics that reveal management is currently unable to generate positive returns on the capital invested by shareholders or the company's asset base.
Valuation Assessment
The trailing twelve-month P/E ratio is listed as N/A due to the net loss, whereas the forward P/E is 24.63, implying that the market prices in significant expected earnings recovery or stability for the coming year. The price-to-book ratio is 1.21, suggesting that the market values the company at a slight premium over its net asset value, potentially reflecting intangible assets like intellectual property or brand equity within the diagnostics sector. Alternative valuation metrics include a price-to-sales ratio of 1.40 and an EV/EBITDA of -697.51, which highlights that traditional earnings-based multiples are distorted by current losses and that valuation relies heavily on revenue multiples and future cash flow potential. Regarding trading range, the stock has a 52-week high of $13.74 and a 52-week low of $4.72, meaning the current price sits within the lower to middle portion of its annual trading range relative to the volatility observed over the past year. The beta value is 1.64, indicating that the stock exhibits price volatility that is substantially higher than the broader market, reacting with greater magnitude to market movements compared to a standard equity index.
Growth & Income
Revenue growth year-over-year is recorded at 10.6%, while earnings growth is N/A, indicating that while top-line sales are expanding, the company has not yet achieved profitability necessary to calculate a meaningful year-over-year earnings expansion rate. The company does not pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which implies that earnings are being retained entirely for operational needs, debt reduction, or reinvestment into research and laboratory capabilities rather than distribution to shareholders. Consequently, the firm prioritizes capital allocation toward growth initiatives and balance sheet strengthening over income generation for investors seeking current yield. The overall growth and income profile is characterized by double-digit revenue expansion paired with a complete absence of dividend income, reflecting a growth-oriented strategy typical of capital-intensive diagnostic laboratories still navigating toward consistent profitability.